XML 101 R91.htm IDEA: XBRL DOCUMENT v3.21.1
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 12, 2021
Feb. 25, 2021
Feb. 23, 2021
Mar. 31, 2017
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Dec. 31, 2019
Mar. 09, 2021
Provision for losses         $ 1,000,000      
MTIX Limited [Member]                  
Proceeds from sale of shares             $ 1,200,000    
MTIX Limited [Member] | Multiplex Laser Surface Enhancement [Member]                  
Purchase order       $ 50,000,000          
AVLP [Member] | Loan And Security Agreement [Member]                  
Principal amount         $ 13,900,000        
Number of shares acquired         999,175        
Contractual interest receivable         $ 2,000,000        
Unrealized gain         $ 71,000        
Number of warrants purchased         27,800,000        
Provision for losses         $ 3,400,000        
AVLP [Member] | Loan And Security Agreement [Member] | Convertible Promissory Note [Member]                  
Interest rate on debt         12.00%        
Alzamend. [Member]                  
Short-term advance         $ 750,000        
Convertible promissory note aggregate principal amount         $ 50,000        
Fair value of common stock         $ 1.50        
Interest rate on debt         8.00%        
Number of warrants purchased         16,667        
Warrant tem         5 years        
Alzamend. [Member] | Securities Purchase Agreement [Member]                  
Investment in common stock and warrants $ 10,000,000                
Funded amount $ 4,000,000                
Description of reamaining funded amount The remaining $6.0 million will be funded upon Alzamend achieving certain milestones related to the U.S. Food and Drug Administration approval of Alzamend’s Investigational New Drug application and Phase 1a human clinical trials for Alzamend’s lithium based ionic cocrystal therapy, known as AL001.                
Description of agreement Alzamend has agreed to sell up to 6,666,667 shares of its common stock to DP Lending for $10.0 million, or $1.50 per share, and issue to DP Lending warrants to acquire up to 3,333,334 shares of Alzamend common stock with an exercise price of $3.00 per share.                
Convertible promissory note aggregate principal amount                 $ 800,000
Fair value of common stock                 $ 1.14
Alzamend. [Member] | Securities Purchase Agreement [Member] | Common Stock [Member]                  
Number of shares acquired             427,888    
Amount of shares issued             $ 252,000    
Alzamend. [Member] | Securities Purchase Agreement [Member] | DPW Holdings [Member]                  
Convertible promissory note aggregate principal amount         $ 800,000        
Unrealized gain         $ 236,000        
Alzamend. [Member] | Securities Purchase Agreement [Member] | DPW Holdings [Member] | Common Stock [Member]                  
Number of shares acquired               427,888  
Amount of shares issued               $ 252,000  
Ault & Company, Inc. [Member] | 8% Secured Promissory Note [Member]                  
Principal amount   $ 2,500,000              
Interest rate on debt   8.00%              
Due and payable date   Feb. 25, 2022              
Ault & Company, Inc. [Member] | 8% Secured Promissory Note [Member] | Series B Preferred Stock [Member]                  
Number of shares issued (in shares)   125,000              
Mr. Ault's [Member] | CALIFORNIA                  
Purchase amount of residence     $ 2,700,000